U.S. Communications Stock News

NasdaqCM:OSPN
NasdaqCM:OSPNSoftware

OneSpan (OSPN) Q1 EPS Stability Tests Bearish Earnings Decline Narrative

OneSpan (OSPN) Q1 2026 earnings snapshot OneSpan (OSPN) has opened 2026 with Q1 revenue of US$65.9 million and basic EPS of US$0.31, setting the tone for investors assessing how the business is converting its software demand into bottom line results. Over the past year, the company has seen trailing twelve month revenue sit at US$245.8 million with basic EPS of US$1.84, alongside earnings growth of 20.4% and net margins at 28.5% compared to 24% a year earlier. This provides useful context for...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

LPL Financial Holdings (LPLA) Q1 EPS Strength Tests Margin And Volatility Concerns

LPL Financial Holdings (LPLA) opened 2026 with Q1 revenue of about US$4.8b and basic EPS of US$4.45, as investors weigh these headline figures against a reported net margin of 5% over the trailing 12 months that was affected by a US$732.0m one off loss. The company has seen quarterly revenue move from US$3.4b in Q4 2024 to US$3.6b in Q1 2025 and then to about US$4.8b in Q1 2026. Over the last six reported periods, trailing 12 month basic EPS has ranged from US$14.17 to US$11.25, placing...
NasdaqCM:JBIO
NasdaqCM:JBIOBiotechs

Jade Biosciences Reshapes Clinical Leadership As Valuation Debate Persists

Jade Biosciences (NasdaqCM: JBIO) appointed Edward R. Conner, M.D. as Chief Medical Officer. The company elevated Andrew King, M.D., Ph.D. to President, Research & Development. These leadership changes focus on clinical development, regulatory strategy, and R&D continuity for Jade's autoimmune pipeline. Jade Biosciences, listed on NasdaqCM under the ticker JBIO, is focused on developing therapies for autoimmune conditions, an area that continues to attract capital and partnerships across...
NYSE:PBF
NYSE:PBFOil and Gas

PBF Energy (PBF) Q1 EPS Rebound Tests Bullish Margin Narratives

PBF Energy (PBF) opened 2026 with Q1 revenue of US$7.9b and basic EPS of US$1.69, alongside net income excluding extra items of US$198.3m, setting a clear marker after a volatile run of recent quarters. The company has seen quarterly revenue move from US$7.1b in Q1 2025 to US$7.9b in Q1 2026, while EPS shifted from a loss of US$3.53 in Q1 2025 to a profit of US$1.69 in the latest period. This points to a very different margin profile as investors gauge how durable this reset may be. See our...
NYSE:DAL
NYSE:DALAirlines

Is It Time To Reassess Delta Air Lines (DAL) After Its 58% One Year Rally?

Wondering whether Delta Air Lines at around US$68.98 is offering good value or stretching expectations? This article will help you size up the stock through a clear valuation lens. The share price has moved by 0.8% over the last 7 days and 2.0% over the last 30 days, with a 1 year return of 58.0% and a 3 year return of 109.5%, while the year to date figure sits at a slight 0.1% decline. Recent headlines have focused on Delta Air Lines in the context of broader airline sector themes,...
NasdaqGS:AUR
NasdaqGS:AURSoftware

Is It Time To Reconsider Aurora Innovation (AUR) After Its Recent Share Price Surge?

Investors may be wondering whether Aurora Innovation's share price reflects its true worth, or if the market is mispricing the story right now. The stock recently closed at US$6.13, with returns of 24.8% over 7 days, 46.7% over 30 days, 58.4% year to date, and a 24.7% decline over the past year, alongside a very large gain over 3 years. Recent coverage has focused on how autonomous driving and AI related names are being reassessed by investors, as attention shifts to companies tied to real...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price

If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can help frame your next move. The stock has seen sharp swings recently, with returns of 11.6% over 7 days, 22.5% over 30 days, 34.6% year to date, but a 29.3% decline over the past year and gains of 113.6% over 3 years and 143.7% over 5 years. Recent coverage has focused on how this price history shapes expectations for Corcept...
NYSE:TRV
NYSE:TRVInsurance

Is Travelers Companies (TRV) Pricing Reflecting Its Recent Share Gains And Earnings Valuation?

For investors considering whether Travelers Companies at around US$304.72 represents fair value or whether the price may be ahead of itself, this article examines what the available numbers indicate about the stock. The share price has moved by 0.7% over the past week, 4.9% over the last month, 6.8% year to date and 15.8% over the past year. These figures provide useful context before assessing the underlying value. Recent news coverage has focused on Travelers Companies as a major U.S...
NasdaqGS:CARG
NasdaqGS:CARGInteractive Media and Services

A Look At CarGurus (CARG) Valuation As Shares Trade Near Analyst Fair Value Estimates

Why CarGurus Stock Is on Investors’ Radar CarGurus (CARG) has drawn investor interest after recent trading left the shares around US$37.04, with returns over the past month and past 3 months outpacing its year to date performance. See our latest analysis for CarGurus. That recent move to US$37.04 follows a 10.4% 30 day share price return and a 14.3% 90 day share price return, set against a year to date share price return that is slightly negative and a 31.4% 1 year total shareholder return...
NYSE:OHI
NYSE:OHIHealth Care REITs

Omega Healthcare Investors (OHI) Q1 FFO Highlights Tenant Risk Narrative Tension

Omega Healthcare Investors (OHI) opened 2026 with Q1 revenue of US$323 million and basic EPS of US$0.47, alongside funds from operations of US$249 million and FFO per share of US$0.84, setting a clear snapshot of cash generation and earnings at the start of the year. Over the past reported quarters, revenue has moved from US$277 million in Q1 2025 to US$319 million in Q4 2025 and EPS has ranged between US$0.34 and US$0.60 over that period. This gives investors a recent history of how the top...
NYSE:AHR
NYSE:AHRHealth Care REITs

Is It Too Late To Consider American Healthcare REIT (AHR) After 58% One-Year Rally?

Wondering if American Healthcare REIT is reasonably priced at around US$50 a share, or if the market is getting ahead of itself? This article walks through what the current numbers actually say about value. The stock recently closed at US$50.15, with returns of 0.1% over 7 days, 5.5% over 30 days, 6.2% year to date and 57.7% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on American Healthcare...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

Align Technology (ALGN) Margin Resilience Reinforces Bullish Narratives After Q1 2026 Earnings

Align Technology (ALGN) opened 2026 with Q1 revenue of about US$1.0 billion and basic EPS of US$1.58, setting the tone for how investors will read the rest of the year. The company has seen quarterly revenue move from US$979.3 million in Q1 2025 through US$995.2 million in Q4 2024 to just over US$1.0 billion in the latest quarter, while basic EPS over the same span ranged from US$1.27 in Q1 2025 to US$1.89 in Q4 2025 before landing at US$1.58 in Q1 2026. This provides a clear run-rate on both...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

O'Reilly Automotive (ORLY) Earnings Growth Outpaces Five Year Trend Reinforcing Bullish Margin Narrative

O'Reilly Automotive (ORLY) opened 2026 with Q1 revenue of US$4.6b and basic EPS of US$0.72, supported by trailing twelve month revenue of US$18.2b and EPS of US$3.08 that point to earnings growth of 9.5% over the past year. Over the last five reported quarters, the company has seen revenue move from US$4.1b in Q1 2025 to US$4.6b in Q1 2026, while quarterly EPS ranged between US$0.63 and US$0.86 across that period as trailing net income reached US$2.6b. With net profit margins running at...
NasdaqGS:STNE
NasdaqGS:STNEDiversified Financial

Is StoneCo (STNE) Now An Opportunity After Recent Share Price Slide?

This article examines whether StoneCo, trading at around US$10.98, could be considered a bargain or a value trap by focusing on what the current share price might imply about the company. The stock has experienced significant recent volatility, with a 24.5% decline over the last week, a 22.2% decline over the last month, and a 25.3% decline year to date. Over longer periods, the 1 year return shows a 4.3% decline and the 5 year return a 78.3% decline. Recent commentary around StoneCo has...
NYSE:PHM
NYSE:PHMConsumer Durables

A Look At PulteGroup (PHM) Valuation After Recent Share Price Pullback

Why PulteGroup is on investors’ radar today PulteGroup (PHM) is back on many watchlists after recent share price moves, including a 1.4% gain over the last day, a 6.3% decline over the past week, and mixed returns over the month and past 3 months. See our latest analysis for PulteGroup. That short-term pullback, with a 7 day share price return of a 6.3% decline, sits against a much stronger backdrop that includes a 1 year total shareholder return of 21.1% and a 5 year total shareholder return...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects

Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions. The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron. Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects. The presentations focus on combination approaches in obesity and diabetes treatment development. Structure Therapeutics focuses on oral...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Is It Too Late To Consider Camtek (CAMT) After Its 191% One Year Surge

If you are wondering whether Camtek's current share price reflects its underlying value, you are not alone. That question is exactly what this article will help you think through. Camtek's stock has been volatile recently, with a 2% decline over the last week, a 26.6% gain over the last 30 days, a 66.2% return year to date, and a 191.3% return over the last year, along with very large multi year gains. These moves have put Camtek firmly on many investors' radars, and recent coverage has...
NYSE:TFC
NYSE:TFCBanks

Is It Too Late To Consider Truist Financial (TFC) After A 39.9% One Year Return?

Wondering if Truist Financial at around US$51.50 is offering good value right now, or if the easy gains are already behind it. The stock recently closed at US$51.50, with returns of 0.2% over 7 days, 12.0% over 30 days, 3.5% year to date, 39.9% over 1 year and 6.8% over 5 years, which provides a range of recent pricing data to consider. Recent coverage around Truist Financial has focused on its position in the U.S. banking sector and how investors are reassessing established banks. This...
NYSE:SWX
NYSE:SWXGas Utilities

A Look At Southwest Gas Holdings (SWX) Valuation After Recent Share Price Momentum

Why Southwest Gas Holdings (SWX) is on investors’ radar Southwest Gas Holdings (SWX) has drawn attention after a sustained stretch of positive returns, including gains over the past week, month, past 3 months and year. This performance is prompting investors to reassess the utility’s current share price. See our latest analysis for Southwest Gas Holdings. The recent 1 month share price return of 8.23% and year to date share price return of 17.34% suggest building momentum, while the 1 year...
NYSE:AZO
NYSE:AZOSpecialty Retail

How Investors Are Reacting To AutoZone (AZO) Debt-Funded Buybacks Amid EV Shift And Higher Rates

In recent years, AutoZone's heavy reliance on debt-funded share buybacks has left the company with liabilities that appear to exceed its assets, raising concerns about the durability of a business model that has produced very large long-term returns for shareholders in the past. These worries are being amplified by higher interest rates and the gradual shift toward electric vehicles, which together may challenge AutoZone's historically dependable cash generation and financial flexibility...
NYSE:CLX
NYSE:CLXHousehold Products

Clorox’s Purell Deal Expands Health Focus As Earnings Outlook Softens

Clorox, NYSE:CLX, has completed its acquisition of GOJO Industries, the owner of the Purell brand. The deal adds a broad health and hygiene portfolio to Clorox's existing cleaning and household products. This transaction reflects a move to broaden Clorox's exposure beyond traditional household categories. Clorox enters this deal with its shares at $96.44, after a 27.3% decline over the past year and a 38.1% decline over the past five years. The acquisition of GOJO and Purell gives the...
NasdaqGS:ODFL
NasdaqGS:ODFLTransportation

Old Dominion Freight Line (ODFL) Valuation Check After Strong 1 Year Shareholder Return

Why Old Dominion Freight Line is on investors’ radar now Old Dominion Freight Line (ODFL) has attracted fresh attention after a strong run in its shares over the past year, with returns outpacing shorter term moves over the month and past 3 months. With the stock recently closing at $212.43 and 1 year total return at 42.08%, investors are weighing how the company’s current valuation lines up against its recent revenue and net income figures. See our latest analysis for Old Dominion Freight...
NYSE:LHX
NYSE:LHXAerospace & Defense

L3Harris Technologies (LHX) Heads Into Q1 2026 With 7.3% Net Margin Reinforcing Bullish Narratives

L3Harris Technologies (LHX) has kicked off its Q1 2026 reporting cycle with investors looking back at a steady run of quarterly numbers, where 2025 revenue ranged from US$5,132 million to US$5,659 million and basic EPS moved between US$1.60 and US$2.47. Over the last year, the company has seen total revenue hold around US$21.2 billion on a trailing basis, while trailing EPS has tracked between US$7.91 and US$9.35. This provides a clear sense of consistent top line scale and earnings power as...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Is It Too Late To Consider Warner Bros. Discovery (WBD) After 221% One Year Surge?

If you are wondering whether Warner Bros. Discovery at around US$27.05 is still offering value after a strong run, this breakdown will help you understand what the current price actually reflects. The stock has returned 0.6% over the last week and 220.9% over the past year, even though the year to date return sits at a 5.1% decline and the five year return is a 25.4% decline. Recent headlines have focused on Warner Bros. Discovery's positioning across streaming, film, and TV content, as...